Deca Durabolin injection contains the active ingredient nandrolone decanoate, which is a type of medicine called an anabolic steroid. Anabolic steroids have the same properties as the natural hormone testosterone. They are believed to increase the production of protein by the body and to enhance muscle development. Nandrolone also causes masculinisation in men who are deficient in natural male hormones, however in men with no testosterone deficiency, it actually reduces sperm production. Nandrolone injection is licensed to treat osteoporosis in women who have passed the menopause, however, this is no longer a recommended treatment for osteoporosis. In osteoporosis there is loss of bone tissue, resulting in bones that are brittle and liable to fracture. Nandrolone works by influencing the metabolism of calcium (an important constituent of bone and teeth) and thereby increasing bone mass in women suffering from osteoporosis. This makes the bones stronger and less likely to break. Deca Durabolin injection contains nandrolone decanoate in a peanut oil (arachis oil) base, which releases the active ingredient slowly over a period of up to three weeks. This is known as a “depot” injection. The injection is given into a muscle (usually the buttock) every three weeks.
Effects of Deca Durabolin
Cardiovascular effects may be precipitated in patients adversely affected by fluid retention. Edema, with and without congestive heart failure, has occurred during Anabolic Steroid therapy.
Genitourinary effects following chronic administration and/or large dosages of Anabolic Steroids can result in oligospermia and decreased ejaculatory volume. Elderly male patients may experience prostatic enlargement resulting in urinary obstruction. Priapism and excessive stimulation may develop. Female patients may experience virilization including deepening voice, hirsutism, acne, clitomegaly (not reversible), and menstrual abnormalities. Discontinuation of medication at signs of mild virilization may prevent irreversible virilization. Alterations in libido may occur (increased/decreased).
Life-threatening peliosis hepatis and hepatic abnormalities such as hepatic neoplasms and hepatocellular carcinomas have occurred following prolonged therapy with high doses of Anabolic Steroids. Tumor regression did not occur in all cases following medication withdrawal. Cholestatic hepatitis, jaundice, and abnormal liver function tests may occur at relatively low dosages.
Hepatic tumors associated with Anabolic Steroid use are more vascular than other hepatic tumors and may remain silent until the development of life-threatening abdominal hemorrhage. Peliosis hepatis may present as mild liver dysfunction, but has resulted in liver failure.
Female patients may experience virilization including deepening voice, hirsutism, acne, clitomegaly (not reversible), and menstrual abnormalities. Discontinuation of Anabolic Steroids at signs of mild virilization may prevent irreversible virilization.
Musculoskeletal effects of Anabolic Steroids involve closure of the epiphyseal growth centers by termination of linear bone growth. Appropriate monitoring of bone age is recommended during use in prepubertal patients.
Oncologic effects following prolonged therapy with large doses of Anabolic Steroids have included hepatic neoplasms and hepatocellular carcinomas.
Hematologic effects occurring during Anabolic Steroid therapy included alterations in clotting factors II, V, VII and X , prolonged prothrombin time (PT), and increased red cell production.